Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma, Follicular 1Lymphedema 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia 1Graft vs Host Disease 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Docetaxel 7acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Prednisone 5Androgen Antagonists 5gallium 68 PSMA-11 4enzalutamide 3bicalutamide 3Triptorelin Pamoate 3Radiosurgery 3Leuprolide 3Goserelin 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3abiraterone 2Zoledronic Acid 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Mitoxantrone 2Flutamide 2Celecoxib 2Abiraterone Acetate 2satraplatin 1relugolix 1pertuzumab 1nilutamide 1maltodextrin 1luprolide acetate gel depot 1histrelin 1genistein combined polysaccharide 1fluciclovine F-18 1darolutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Prostatic Neoplasms × Tacrolimus × Clear all
NCT00922129 2014-01-14

Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer

St. Joseph's Healthcare Hamilton

Phase 2/3 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡